Sign In
Buy OCUL
$8.35
+0.0400 (+0.481%)
At Close: Jun 03, 2026
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
07:00am, Tuesday, 02'nd Jun 2026
In addition to Ocular leadership, event to feature prominent retinal disease experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Lejla Vajzovic, MD, FASRS; and Dr. Darius M.
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1
06:06pm, Tuesday, 26'th May 2026
Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targeting multiple ocular diseases.
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
01:06pm, Tuesday, 19'th May 2026
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 15'th May 2026
BEDFORD, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina
Ocular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
10:00pm, Tuesday, 12'th May 2026
Ocular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 08'th May 2026
BEDFORD, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina
Ocular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call Transcript
02:41pm, Tuesday, 05'th May 2026
Ocular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call Transcript
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
10:16am, Tuesday, 05'th May 2026
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.37 per share a year ago.
Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
07:00am, Tuesday, 05'th May 2026
Enrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year follow-up in SOL-1 or SOL-R Announced positive Phase 3 SOL-1 results in February 2026, first ever suc
Ocular Therapeutix Says FDA Talks Progressing as It Eyes AXPAXLI NDA for Wet AMD on SOL-1 Data
02:21pm, Wednesday, 29'th Apr 2026
Ocular Therapeutix (NASDAQ: OCUL) Executive Chairman, President, and CEO Dr. Pravin Dugel said the company is engaged in formal discussions with the U.S. Food and Drug Administration as it works towar
Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD
07:00am, Wednesday, 29'th Apr 2026
SOL-X long-term extension trial in wet AMD enrolled the first subject in April 2026 who had successfully completed the two-year SOL-1 trial Subjects who have completed the two-year follow-up in eith
Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026
07:00am, Tuesday, 28'th Apr 2026
BEDFORD, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today a
Ocular Therapeutix, Inc. $OCUL Stock Position Lessened by Deltec Asset Management LLC
05:11am, Monday, 27'th Apr 2026
Deltec Asset Management LLC cut its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ: OCUL) by 9.9% during the fourth quarter, according to the company in its most recent Form 13F filing with th
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
07:00am, Wednesday, 22'nd Apr 2026
Ocular's Investor Day will take place in New York City, with virtual access available, starting at 2:00 PM ET on Wednesday, June 17, 2026 Ocular's Investor Day will take place in New York City, with v
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD
07:00am, Monday, 13'th Apr 2026
New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI's unmatched durability in wet AMD with sustained disease control
